Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 387

Sort by

Sort Order Select

Journal Articles

Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018

D. E. Issa, R. L. Seefat, O. Visser, S. Zweegman, P. J. Lugtenburg, A. G. Dinmohamed, M. E. D. Chamuleau

Blood (2021) 137 (20): 2848–2851.

https://doi.org/10.1182/blood.2020009552

Published: 2021

Includes: Supplemental data

Journal Articles

Iron Restriction Improves Markers of Disease Severity in the Townes Mouse Model of Sickle Cell Anemia

Nermi Parrow, PhD, Pierre-Christian Violet, PhD, Nisha George, PhD, Faris Ali, Shivam Bhanvadia, Mark Levine, MD, Robert E Fleming, MD

Blood (2019) 134 (Supplement_1): 2261.

https://doi.org/10.1182/blood-2019-130732

Published: 2019

Journal Articles

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Minke A.E. Rab, MD, Richard van Wijk, PhD, Celeste K. Kanne, BA, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, MD, Jorn J. Gerritsma, MD, Karin Fijnvandraat, MD PhD, Celine Renoux, PhD, Marije Bartels, MD PhD, Erfan Nur, MD PhD, Marjon H. Cnossen, MD PhD, Philippe Joly, PhD, Romain Fort, MD, Philippe Connes, PhD, Eduard J. van Beers, MD PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 2275.

https://doi.org/10.1182/blood-2019-128870

Published: 2019

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

Peripheral Neuropathy and Hypovitaminosis D Are Associated in Multiple Myeloma Patients

Berdien Oortgiesen, Hans Kroes, Petra Scholtens, Jitske Hoogland, Pauline Dannenberg-de Keijzer, Claire Siemes, MD PhD, Frank Jansman, Robby Kibbelaar, Dr., Nic Veeger, Dr., Mels Hoogendoorn, Dr., Eric van Roon, Prof. Dr.

Blood (2019) 134 (Supplement_1): 5506.

https://doi.org/10.1182/blood-2019-130611

Published: 2019

Journal Articles

Role of Disease Modifying Treatment in the Risk of Alloimmunization in Transfused Patients with Myelodysplastic Syndromes: A Population-Based Study

Hanne Rozema, MSc, Robby Kibbelaar, Dr., Nic Veeger, Dr., Mels Hoogendoorn, Dr., Eric van Roon, Prof. Dr.

Blood (2019) 134 (Supplement_1): 4253.

https://doi.org/10.1182/blood-2019-123357

Published: 2019

Journal Articles

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Blood (2019) 134 (Supplement_1): 2719.

https://doi.org/10.1182/blood-2019-131211

Published: 2019

Journal Articles

Impact of KIR/HLA Incompatibilities after Posttransplant Cyclophosphamide Based T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation

Sarah Lindner, MD, Tobias Berg, MD, Christian Seidel, Franziska Kalensee, Michael A. Rieger, Hubert Serve, MD, Gesine Bug, Joachim Schwaeble, Evelyn Ullrich, MD

Blood (2019) 134 (Supplement_1): 3340.

https://doi.org/10.1182/blood-2019-125243

Published: 2019

Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 3162.

https://doi.org/10.1182/blood-2019-123547

Published: 2019

Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 604.

https://doi.org/10.1182/blood-2019-124819

Published: 2019

Journal Articles

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Bart J. Biemond, MD PhD, Anil Tombak, MD, Yurdanur Kilinc, MD, Murtadha Al-Khabori, MD, Miguel R. Abboud, MD, Mohammed Nafea, MD, Adlette Inati, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Jens Kristensen, MD PhD, Ellen Donnelly, PhD, John Ohd, MD PhD

Blood (2019) 134 (Supplement_1): 614.

https://doi.org/10.1182/blood-2019-124653

Published: 2019

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD

Ferdows Atiq, Lisette M. Schütte, MD, Agnes E.M. Looijen, Bsc, Johan Boender, MD, Moniek P.M. de Maat, PhD, Marieke J.H.A. Kruip, MD PhD, Frank W.G. Leebeek, MD PhD

Blood (2019) 134 (Supplement_1): 1116.

https://doi.org/10.1182/blood-2019-123634

Published: 2019

Journal Articles

Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias

Annelies J. Van Vuren, MD, Michele F. Eisenga, MD PhD, Stephanie van Straaten, MD PhD, Andreas Glenthøj, MD PhD, Carlo A.J.M. Gaillard, MD PhD, Stephan J.L. Bakker, MD PhD, Martin H. de Borst, MD PhD, Richard van Wijk, PhD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 4793.

https://doi.org/10.1182/blood-2019-124074

Published: 2019

Journal Articles

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Shoshana Revel-Vilk, MD, Jeffrey Szer, MBBS, Michal Becker Cohen, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4862.

https://doi.org/10.1182/blood-2019-131013

Published: 2019

Journal Articles

Red Blood Cell Deformability Demonstrated with the Oxygenscan: Exploring the Association with Hydroxyurea Treatment, Co-Inherited α-Thalassemia, and Frequency of Pain in Children with Sickle Cell Anemia

Amina Nardo-Marino, Jesper Petersen, Andreas Glenthoej, MD PhD, John N. Brewin, Joergen Kurtzhals, Thomas N. Williams, David C. Rees, Henrik Birgens

Blood (2019) 134 (Supplement_1): 4834.

https://doi.org/10.1182/blood-2019-129836

Published: 2019

Journal Articles

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Elena Zamagni, MD, Sujith Dhanasiri, Adam Moore, Arun Ghale, Murielle Roussel, MD

Blood (2019) 134 (Supplement_1): 4772.

https://doi.org/10.1182/blood-2019-123629

Published: 2019

Journal Articles

Improving Access to Healthcare for Pediatric Sickle Cell Disease Patients and Their Families

Maite E. Houwing, MD, Marit Buddenbaum, MA, LLM, Thijs C.J. Verheul, BSc, Anne P.J. de Pagter, MD PhD, Jan A Hazelzet, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2019) 134 (Supplement_1): 4835.

https://doi.org/10.1182/blood-2019-129892

Published: 2019

Journal Articles

A Test to Quantify NOTCH Pathway Activity in T Cell Acute Lymphoblastic Leukemia Patients

Kirsten Canté-Barrett, PhD, Laurent Holtzer, PhD, Henk van Ooijen, PhD, Rico Hagelaar, Valentina Cordo', MSc, Wim Verhaegh, PhD, Anja van de Stolpe, MD PhD, Jules P.P. Meijerink, PhD

Blood (2019) 134 (Supplement_1): 4661.

https://doi.org/10.1182/blood-2019-122856

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018

Iron Restriction Improves Markers of Disease Severity in the Townes Mouse Model of Sickle Cell Anemia

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Peripheral Neuropathy and Hypovitaminosis D Are Associated in Multiple Myeloma Patients

Role of Disease Modifying Treatment in the Risk of Alloimmunization in Transfused Patients with Myelodysplastic Syndromes: A Population-Based Study

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Impact of KIR/HLA Incompatibilities after Posttransplant Cyclophosphamide Based T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD

Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Red Blood Cell Deformability Demonstrated with the Oxygenscan: Exploring the Association with Hydroxyurea Treatment, Co-Inherited α-Thalassemia, and Frequency of Pain in Children with Sickle Cell Anemia

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Improving Access to Healthcare for Pediatric Sickle Cell Disease Patients and Their Families

A Test to Quantify NOTCH Pathway Activity in T Cell Acute Lymphoblastic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only